FDA grants fast track designation for LYT-200 in combination with anti-PD1 therapy for head and neck squamous cell cancer.
FDA grants fast track designation to LYT-200 for head and neck squamous cell cancer (HNSCC) in combination with anti-PD1 therapy. LYT-200, a fully human monoclonal antibody targeting galectin-9, is currently in phase 1b and phase 1/2 clinical trials for HNSCC and hematological malignancies. The FDA's fast track designation aims to expedite the development and assessment of drugs with unmet medical needs.
April 11, 2024
6 Articles